BioSpace News Archive

A conference call to discuss the financial results will be held Tuesday December 18th, 2018, at 9:00am EST.

FOCUS study met all primary and secondary endpoints in both the quarterly and monthly dosing regimens in patients with chronic and episodic migraine

Company to utilize CBD isolate for distribution of wellness and medical products across North America

The Scleroderma Research Foundation’s flagship event featured Bob Saget, Jackson Browne, Michael Che, Andy Cohen, John Oliver, Jeff Ross, and Top Chef Masters

Both treatment naïve and treatment refractory individuals experienced improved visual acuity

Publication Highlights Bryostatin’s Neurorestorative Potential in the Most Challenging-to-treat and Underserved AD Patient Population

Online, non-profit university presents Elizabeth Leal with $2,000 Award

Neurotrope (NASDAQ:NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease (AD), today announced the appointment of two new members to its Board of Directors - Ivan Gergel, M.D., Managing Partner and Chief Medical Officer of New Rhein Healthcare Investors LLC, and Jonathan Schechter, Director of Investment Banking at Chardan Capital Markets.

Brightree to innovate and expand adoption of Apacheta’s mobile delivery solution to more HME customers

Ayala Pharmaceuticals, Inc., a clinical-stage company developing medicines for cancers that are genetically identified, today announced that the first patient has been enrolled in its Phase 2 ACCURACY study, to evaluate lead investigational candidate AL101 in patients with adenoid cystic carcinoma (ACC) bearing Notch activated mutations.